Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Price:
5.29 USD
1.54%
Market Closed
Updated:
May 29, 2024
Aurinia Pharmaceuticals Inc
Cash & Cash Equivalents
|
Aurinia Pharmaceuticals Inc
Cash & Cash Equivalents Peer Comparison
Comparables:
ZYME
TH
RPTX
FUSN
EDT
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash & Cash Equivalents
$63.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
34%
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash & Cash Equivalents
$157.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash & Cash Equivalents
$38.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
69%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash & Cash Equivalents
$111.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash & Cash Equivalents
$61.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash & Cash Equivalents
CA$2.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
See Also
What is Aurinia Pharmaceuticals Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
63.9m
USD
63.9m
USD
Based on the financial report for Mar 31, 2024, Aurinia Pharmaceuticals Inc's Cash & Cash Equivalents amounts to 63.9m USD.
What is Aurinia Pharmaceuticals Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
34%
34%
Over the last year, the Cash & Cash Equivalents growth was -28%. The average annual Cash & Cash Equivalents growth rates for Aurinia Pharmaceuticals Inc have been -26% over the past three years , -15% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet
